MX2018005252A - Tratamiento de la oligo-ovulacion relacionada con esteatosis hepatica. - Google Patents

Tratamiento de la oligo-ovulacion relacionada con esteatosis hepatica.

Info

Publication number
MX2018005252A
MX2018005252A MX2018005252A MX2018005252A MX2018005252A MX 2018005252 A MX2018005252 A MX 2018005252A MX 2018005252 A MX2018005252 A MX 2018005252A MX 2018005252 A MX2018005252 A MX 2018005252A MX 2018005252 A MX2018005252 A MX 2018005252A
Authority
MX
Mexico
Prior art keywords
ovulation
treatment
hepatic steatosis
related oligo
steatosis related
Prior art date
Application number
MX2018005252A
Other languages
English (en)
Inventor
Ibáñez Lourdes
De Zegher Francis
Original Assignee
Univ Leuven Kath
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Leuven Kath filed Critical Univ Leuven Kath
Publication of MX2018005252A publication Critical patent/MX2018005252A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Reproductive Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se relaciona con un método y una composición para utilizarse en el tratamiento de una condición que se beneficie de la reducción de grasa hepática y/o visceral, tal como el síndrome de ovario poliquístico en niñas adolescentes o mujeres en edad fértil, que implica el uso de espironolactona, pioglitazona y metformina.
MX2018005252A 2015-10-27 2016-10-27 Tratamiento de la oligo-ovulacion relacionada con esteatosis hepatica. MX2018005252A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1518979.8A GB201518979D0 (en) 2015-10-27 2015-10-27 Treatment of hepatic steatosis related oligo-ovulation
PCT/EP2016/075953 WO2017072243A1 (en) 2015-10-27 2016-10-27 Treatment of hepatic steatosis related oligo-ovulation

Publications (1)

Publication Number Publication Date
MX2018005252A true MX2018005252A (es) 2018-09-18

Family

ID=55130283

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2018005252A MX2018005252A (es) 2015-10-27 2016-10-27 Tratamiento de la oligo-ovulacion relacionada con esteatosis hepatica.
MX2021007976A MX2021007976A (es) 2015-10-27 2018-04-26 Una composicion farmaceutica para usarse en el tratamiento de exceso de grasa hepatica y/o visceral.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2021007976A MX2021007976A (es) 2015-10-27 2018-04-26 Una composicion farmaceutica para usarse en el tratamiento de exceso de grasa hepatica y/o visceral.

Country Status (24)

Country Link
US (2) US20190060328A1 (es)
EP (2) EP3892281A3 (es)
JP (2) JP6999903B2 (es)
KR (1) KR102608158B1 (es)
CN (2) CN108778285A (es)
AR (1) AR106505A1 (es)
AU (1) AU2016344737C1 (es)
BR (1) BR112018008496A2 (es)
CA (1) CA3003076C (es)
DK (1) DK3368044T3 (es)
ES (1) ES2883282T3 (es)
GB (1) GB201518979D0 (es)
HU (1) HUE055778T2 (es)
IL (1) IL258876B (es)
LT (1) LT3368044T (es)
MA (2) MA43106B1 (es)
MX (2) MX2018005252A (es)
PL (1) PL3368044T3 (es)
RS (1) RS62764B1 (es)
RU (1) RU2745606C2 (es)
SI (1) SI3368044T1 (es)
TW (1) TWI791420B (es)
UY (1) UY36967A (es)
WO (1) WO2017072243A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3727468A4 (en) 2017-12-19 2021-09-22 Akouos, Inc. AAV-MEDIATED DELIVERY OF THERAPEUTIC ANTIBODIES TO THE INNER EAR
KR20210045404A (ko) 2018-08-02 2021-04-26 오스피탈 산트 호안 데 데우 다낭성 난소 증후군 치료에 유용한 활성 약학적 성분들의 삼중 조합의 즉시 방출 제제
EP3842803A1 (en) * 2019-12-23 2021-06-30 Katholieke Universiteit Leuven Cxcl14 in polycystic ovary syndrome
EP4165195A2 (en) 2020-05-13 2023-04-19 Akouos, Inc. Compositions and methods for treating slc26a4-associated hearing loss
AU2021391433A1 (en) 2020-12-01 2023-06-22 Akouos, Inc. Anti-vegf antibody constructs and related methods for treating vestibular schwannoma associated symptoms
CA3203373A1 (en) 2020-12-29 2022-07-07 Emmanuel John Simons Compositions and methods for treating clrn1-associated hearing loss and/or vision loss
AR128422A1 (es) 2022-02-02 2024-05-08 Akouos Inc Construcciones de anticuerpos anti-vegf y métodos relacionados para el tratamiento de los síntomas asociados al schwannoma vestibular

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6046222A (en) * 1993-09-15 2000-04-04 Warner-Lambert Company Use of thiazolidinedione derivatives in the treatment of polycystic ovary syndrome, gestational diabetes and disease states at risk for progressing to noninsulin-dependent diabetes mellitus
US5457109A (en) * 1993-09-15 1995-10-10 Warner-Lambert Company Use of thiazolidinedione derivatives and related antihyperglycemic agents in the treatment of disease states at risk for progressing to noninsulin-dependent diabetes mellitus
WO2001062237A2 (en) * 2000-02-23 2001-08-30 Orentreich Foundation For The Advancement Of Science, Inc. Compositions for the treatment of alopecia and other disorders of the pilosebaceous apparatus
GB0106565D0 (en) * 2001-03-16 2001-05-09 Leuven K U Res & Dev Growth hormone treatment
GB0108863D0 (en) * 2001-04-10 2001-05-30 Leuven K U Res & Dev Combinational therapy
US7105489B2 (en) * 2002-01-22 2006-09-12 Amylin Pharmaceuticals, Inc. Methods and compositions for treating polycystic ovary syndrome
EP1581247A4 (en) * 2002-12-11 2007-09-12 Amylin Pharmaceuticals Inc METHODS AND COMPOSITIONS FOR TREATING STEIN-LEVENTHAL SYNDROME
GB0702537D0 (en) * 2007-02-12 2007-03-21 Leuven K U Res & Dev Treatment for excessive adiposity
US10474539B1 (en) * 2015-12-18 2019-11-12 EMC IP Holding Company LLC Browsing federated backups
KR20210045404A (ko) * 2018-08-02 2021-04-26 오스피탈 산트 호안 데 데우 다낭성 난소 증후군 치료에 유용한 활성 약학적 성분들의 삼중 조합의 즉시 방출 제제

Also Published As

Publication number Publication date
TWI791420B (zh) 2023-02-11
AU2016344737A9 (en) 2018-08-09
JP2022009374A (ja) 2022-01-14
US20240000804A1 (en) 2024-01-04
AU2016344737A1 (en) 2018-05-17
CA3003076C (en) 2023-12-05
PL3368044T3 (pl) 2021-12-20
WO2017072243A9 (en) 2018-07-26
EP3368044A1 (en) 2018-09-05
WO2017072243A1 (en) 2017-05-04
US20190060328A1 (en) 2019-02-28
RU2018119146A (ru) 2019-11-28
RU2018119146A3 (es) 2020-02-25
JP2019501113A (ja) 2019-01-17
HUE055778T2 (hu) 2021-12-28
BR112018008496A2 (pt) 2018-10-23
KR102608158B1 (ko) 2023-11-29
IL258876A (en) 2018-06-28
MA43106A (fr) 2021-05-05
CN108778285A (zh) 2018-11-09
RS62764B1 (sr) 2022-01-31
LT3368044T (lt) 2021-10-25
AU2016344737B2 (en) 2021-07-08
MA43106B1 (fr) 2021-09-30
JP6999903B2 (ja) 2022-02-04
EP3892281A2 (en) 2021-10-13
KR20180098234A (ko) 2018-09-03
RU2745606C2 (ru) 2021-03-29
CA3003076A1 (en) 2017-05-04
EP3892281A3 (en) 2021-11-10
AR106505A1 (es) 2018-01-24
TW201720432A (zh) 2017-06-16
CN117379440A (zh) 2024-01-12
ES2883282T3 (es) 2021-12-07
AU2016344737C1 (en) 2021-10-07
MA54412A (fr) 2021-11-10
IL258876B (en) 2022-03-01
DK3368044T3 (da) 2021-09-13
SI3368044T1 (sl) 2022-05-31
WO2017072243A8 (en) 2018-03-22
UY36967A (es) 2017-05-31
GB201518979D0 (en) 2015-12-09
EP3368044B1 (en) 2021-06-09
MX2021007976A (es) 2021-08-16

Similar Documents

Publication Publication Date Title
MX2021007976A (es) Una composicion farmaceutica para usarse en el tratamiento de exceso de grasa hepatica y/o visceral.
HK1254358A1 (zh) 用於治療突觸核蛋白病的藥劑、用途和方法
HK1248590A1 (zh) 用於治療貧血的組合物和方法
IL251215B (en) Cannabinoid preparation and method for treating pain
IL273278A (en) Composition and method for treating autism
IL269637A (en) Preparations and methods for the treatment of synovial diseases
MX2021002851A (es) Reutilizacion de agente cloroso activado para el tratamiento de carne y aves.
HK1256541A1 (zh) 用於處理皮膚的方法和組合物
SG11202000866TA (en) Treatment agent composition for textile products
MX2017006674A (es) Composiciones antimicrobianas y métodos relacionados para tratar productos alimenticios y superficies.
MX2017003301A (es) Producto refractario, relleno para fabricar el producto, procedimiento para fabricar el producto y uso del producto refractario.
MX2017003550A (es) Uso de cisteamina en tratamiento de infecciones causadas por levaduras/mohos.
HK1243635A1 (zh) 治療皮膚病況的組合物和方法
IL269550A (en) Preparations and methods for treating diseases related to alpha-synuclein
ZA201904080B (en) Transalkylation process and catalyst composition used therein
PL3412784T3 (pl) Sposób obróbki wyrobów z nadstopów
IL260331A (en) Compounds and methods for the treatment of amyotrophic lateral sclerosis
IL258629A (en) Methods and preparations for the treatment of traumatic brain damage
IL284181A (en) Products for the treatment of bleeding wounds
IL279907A (en) Preparations and methods for treating stroke
MX2017008776A (es) Relleno para preparar un producto refractario, un procedimiento para preparar un producto refractario, un producto refractario, y uso de un producto refractario.
PL3268347T3 (pl) Mieszaniny związków cheltujących i sposób wytwarzania takich mieszanin
PL3216452T3 (pl) Kompozycja do zapobiegania lub leczenia zapalenia błony śluzowej zawierająca jako skuteczny składnik NecroX
ZA201903931B (en) Method of treating meat
IL269875B2 (en) NK1 antagonist combination and a method for the treatment of synucleinopathies